Forward Pharma files opening brief against PTAB Biogen decision


Forward Pharma has filed its opening brief in an appeal against a decision by the Patent Trial and Appeal Board (PTAB).

Forward Pharma, PTAB, Biogen, patent, US Court of Appeals for the Federal Circuit, multiple sclerosis, patent infringement, Kyle Bass